ATZ en es it fr

ATZ Brand names, ATZ Analogs

ATZ Brand Names Mixture

  • No information avaliable

ATZ Chemical_Formula


ATZ RX_link

ATZ fda sheet


ATZ msds (material safety sheet)

ATZ Synthesis Reference

No information avaliable

ATZ Molecular Weight

704.856 g/mol

ATZ Melting Point

No information avaliable

ATZ H2O Solubility

Free base slightly soluble (4-5 mg/mL)

ATZ State




ATZ Dosage Forms

Capsule (100 mg, 150 mg, or 200 mg)

ATZ Indication

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.

ATZ Pharmacology

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

ATZ Absorption

Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability

ATZ side effects and Toxicity

No information avaliable

ATZ Patient Information

ATZ Organisms Affected

Human immunodeficiency virus